Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25041806 | 0.81 | EPHX1 (0.48) | KMT2AMEN1BTKSMN1; SMN2KDM1A | |
| SCHEMBL23487783 | 0.78 | CDK9 (0.51) | BTKCDK9CCR1L3MBTL1 | |
| SCHEMBL7102135 | 0.78 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2GRM4 | |
| SCHEMBL5548398 | 0.78 | BTK (0.47) | KMT2AMEN1BTKCDK9CCR1 | |
| SCHEMBL3907863 | 0.78 | BTK (0.47) | KMT2AMEN1BTKCDK9CCR1 | |
| SCHEMBL31184662 | 0.78 | POLB (0.47) | BTKSMN1; SMN2CDK9GRM4KDM1A | |
| SCHEMBL31185020 | 0.78 | POLB (0.47) | BTKSMN1; SMN2CDK9GRM4KDM1A | |
| SCHEMBL3900663 | 0.77 | TSHR (0.46) | KMT2AMEN1BTKCDK9CCR1 | |
| SCHEMBL23487782 | 0.77 | CDK9 (0.58) | SMN1; SMN2CDK9 | |
| SCHEMBL18349376 | 0.76 | CDK9 (0.57) | BTKCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339668-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002044126-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | PPIG, PIN1, PPIH | KMT2A 4656/4885MEN1 4855/4885BTK 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.